Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Dr Reddy’s to Commercialise Alvotech’s Denosumab Biosimilar in the US, EU and UK

May 21, 2024

On 21 May 2024, Alvotech and Dr Reddy’s announced that that they have entered into a licence and supply agreement for the commercialisation of AVT03 (denosumab), biosimilar to Amgen’s Prolia® and Xgeva® in the US, EU and UK.

Under the agreement, Alvotech will develop and manufacture the product and Dr Reddy’s will commercialise it exclusively in the US, and semi-exclusively in the EU and UK.  The agreement provides for an up-front payment to Alvotech, with additional payments upon certain regulatory and commercialisation milestones, plus sales-based payments.

Alvotech announced positive top-line results for AVT03 in January 2024, in a study comparing the pharmacokinetics, safety and tolerability of the biosimilar compared to Prolia® in healthy adults.